Glenn Greenberg
Brave Warrior Advisors
Glenn Greenberg Valeant Pharmaceuticals International Inc stake
total: 103
Brave Warrior Advisors VRX trades
- Total transactions:
- 13
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 8
- Held since:
- 2013 Q2 or earlier
- Held for:
- 12+ quarters
- Latest activity:
- 2016 Q2
According to 2026 Q1 report, Glenn Greenberg doesn't hold any Valeant Pharmaceuticals International Inc (VRX) shares. Brave Warrior Advisors has held VRX since at least 2013 Q2 with about 6.66M shares in our earliest available record. Since at least 2013 Q2, Brave Warrior Advisors has made 12 more transactions.
When did Glenn Greenberg sell Valeant Pharmaceuticals International Inc (VRX)?
Glenn Greenberg sold off the entire Valeant Pharmaceuticals International Inc (VRX) position in 2016 Q2.
Estimated cost basis*
- Weighted AVG buy price:
- $92.45
- Weighted AVG sell price:
- $56.73
Glenn Greenberg's historical trades in Valeant Pharmaceuticals International Inc
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2016 Q2
|
0.00%
|
$26.30
|
-100% (-2,034,281)
|
|||
|
2016 Q1
|
2.61%
|
$26.30
|
-67.46% (-4,218,050)
|
|||
|
2015 Q4
|
25.22%
|
$101.65
|
+12.09% (+674,439)
|
|||
|
2015 Q3
|
31.62%
|
$178.38
|
-2.16% (-123,118)
|
|||
|
2015 Q2
|
36.57%
|
$222.15
|
-2.99% (-176,006)
|
|||
|
2015 Q1
|
35.64%
|
$198.62
|
-4.07% (-249,593)
|
|||
|
2014 Q4
|
30.53%
|
$143.11
|
-6.98% (-459,973)
|
|||
|
2014 Q3
|
32.02%
|
$131.20
|
+8.86% (+536,140)
|
|||
|
2014 Q2
|
30.78%
|
$126.12
|
+8.19% (+457,884)
|
|||
|
2014 Q1
|
29.80%
|
$131.83
|
-8.52% (-520,669)
|
|||
|
2013 Q4
|
29.38%
|
$117.40
|
-7.00% (-460,362)
|
|||
|
2013 Q3
|
30.77%
|
$104.33
|
-1.26% (-83,862)
|
|||
|
2013 Q2
|
26.53%
|
$86.08
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.